SecBot SecBot
SECBOTREPLAY Home › Report › RDY

RDY · Dr

DR REDDYS LABORATORIES LTD · 6-K filed Jun 15, 2026 at 06:10 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jun 15, 2026 at 06:10 ET

Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine kinase inhibitor for oncology. The product was a first-to-file and qualifies for 180-day generic exclusivity for this strength. The Bosulif brand had U.S. sales of ~$253.8M over the latest 12 months ended April 2026. This is a positive, event-driven catalyst that expands Dr. Reddy's oncology portfolio, limited to a single strength and a finite exclusivity window.

  • First-to-market launch of Bosutinib Tablets 400mg, generic equivalent of Bosulif, in the United States on June 13, 2026.
  • Product is a first-to-file, eligible for 180-day generic exclusivity for this strength.
  • Brand Bosulif (400mg) had U.S. sales of approximately $253.8 million for the latest 12 months ended April 2026.
  • Dr. Reddy's holds exclusive marketing rights; MSN Laboratories is the development and manufacturing partner.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access